DoP implements PLI scheme for pharmaceuticals with a financial outlay of Rs 15,000 cr
The scheme provides a financial incentive to 55 selected applicants for manufacturing of identified products under three categories for a period of six years
The Department of Pharmaceuticals is implementing the Production Linked Incentive (PLI) Scheme for Pharmaceuticals with a total financial outlay of Rs 15,000 crore and scheme tenure up to FY 2027-28. The scheme provides financial incentives to 55 selected applicants for manufacturing identified products under three categories for a period of six years. The product Category 1 covers drugs such as bio-pharmaceuticals, complex generics, gene therapy drugs, complex excipients, orphan drugs etc. Orphan drugs are those drugs which are used for the treatment of rare diseases. Under the scheme, a total of 8 orphan drugs have been approved for manufacturing. The orphan drugs approved under the PLI scheme for Pharmaceuticals are as follows:
This information was given by the Union Minister of State for Chemicals and Fertilizers Anupriya Patel in Lok Sabha.
- Advertisement -